Re-investigating PLK1 inhibitors as antimitotic agents

Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitot...

Descripción completa

Detalles Bibliográficos
Autores principales: Delacour, Quentin, Gavet, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706940/
https://www.ncbi.nlm.nih.gov/pubmed/29209646
http://dx.doi.org/10.1080/23723556.2017.1356430
Descripción
Sumario:Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells.

Ejemplares similares